Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Impact of body composition on clinical outcomes in metastatic renal cell cancer.

Literature DB >> 22020214

Impact of body composition on clinical outcomes in metastatic renal cell cancer.

Patricia A Tang¹, Daniel Y C Heng, Toni K Choueiri.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 22020214 PMCID： PMC3233281 DOI： 10.1634/theoncologist.2011-0337

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

× No keyword cloud information.

24 in total

1. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.

Authors: Janet E Dancey; Kevin K Dobbin; Susan Groshen; J Milburn Jessup; Andrew H Hruszkewycz; Maria Koehler; Ralph Parchment; Mark J Ratain; Lalitha K Shankar; Walter M Stadler; Lawrence D True; Amy Gravell; Michael R Grever
Journal: Clin Cancer Res Date: 2010-03-09 Impact factor: 12.531

Review 2. Epidemiology and risk factors for kidney cancer.

Authors: Wong-Ho Chow; Linda M Dong; Susan S Devesa
Journal: Nat Rev Urol Date: 2010-05 Impact factor: 14.432

3. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.

Authors: Sylvain Ladoire; Franck Bonnetain; Mélanie Gauthier; Sylvie Zanetta; Jean Michel Petit; Séverine Guiu; Isabelle Kermarrec; Eric Mourey; Frederic Michel; Denis Krause; Patrick Hillon; Luc Cormier; François Ghiringhelli; Boris Guiu
Journal: Oncologist Date: 2011-01-06

4. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy?

Authors: Sandra Steffens; Viktor Grünwald; Kristina I Ringe; Christoph Seidel; Hendrik Eggers; Mark Schrader; Frank Wacker; Markus A Kuczyk; Andres J Schrader
Journal: Oncologist Date: 2011-10-21

Review 5. Energy balance, host-related factors, and cancer progression.

Authors: Stephen D Hursting; Nathan A Berger
Journal: J Clin Oncol Date: 2010-08-09 Impact factor: 44.544

6. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.

Authors: S Antoun; V E Baracos; L Birdsell; B Escudier; M B Sawyer
Journal: Ann Oncol Date: 2010-01-20 Impact factor: 32.976

7. Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.

Authors: Sami Antoun; Laura Birdsell; Michael B Sawyer; Peter Venner; Bernard Escudier; Vickie E Baracos
Journal: J Clin Oncol Date: 2010-01-19 Impact factor: 44.544

8. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study.

Authors: Carla M M Prado; Jessica R Lieffers; Linda J McCargar; Tony Reiman; Michael B Sawyer; Lisa Martin; Vickie E Baracos
Journal: Lancet Oncol Date: 2008-06-06 Impact factor: 41.316

9. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.

Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri
Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544